Drugs / 7-t-butyldimethylsilyl-10-hydroxycamptothecin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01202370 | Sep 2010 → Jul 2011 | cancer | University of Kentucky | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 7-t-butyldimethylsilyl-10-hydroxycamptothecin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01202370 ↗ |
| Action | Inhibit | “inhibit DNA Topoisomerase I” NCT01202370 ↗ |
| Route | Intravenous | “IV Over 1 hour” NCT01202370 ↗ |
| Target | TOP1 | “inhibit DNA Topoisomerase I” NCT01202370 ↗ |